Vektor Medical is a technology company.
Vektor Medical has raised $25.0M across 1 funding round.
Vektor Medical has raised $25.0M in total across 1 funding round.
Vektor Medical has raised $25.0M in total across 1 funding round.
Vektor Medical's investors include Solas BioVentures.
Vektor Medical is a San Diego-based medical technology company developing vMap, the only FDA-cleared, AI-powered, non-invasive software that analyzes standard 12-lead ECG data to generate 2D and 3D maps localizing arrhythmia sources across all four heart chambers in under a minute.[1][3][5] It serves electrophysiologists and hospitals treating cardiac arrhythmias—a global crisis causing 10% of deaths and affecting over 25% of adults over 40—by solving the problem of slow, invasive mapping that delays ablation procedures and worsens outcomes like stroke and dementia.[1][3] vMap is FDA-cleared and CE-marked for seven arrhythmias (atrial/ventricular tachycardia, fibrillation, premature complexes, orthodromic AVRT) plus two pacing types, with recent enhancements for atrial flutter, electroanatomic system integration, and Software as a Medical Device (SaMD) deployment without custom hardware.[1][2][3] Used in over 2,000 procedures across 30+ U.S. hospitals and now expanding to Europe, it drives growth through improved ablation success, reduced procedure times, and seamless workflow integration.[2][7]
Vektor Medical emerged from physician-led innovation to address gaps in arrhythmia mapping, with roots tied to computational ECG advancements though specific founders are not detailed in available sources.[1][4] A pivotal moment came with FDA 510(k) clearance for initial vMap in 2023, enabling commercial U.S. rollout and adoption by pioneers like UC San Diego Health—the world's first hospital system to offer it.[2] Early traction built rapidly: by mid-2023, software upgrades added automation and noise reduction for better accuracy; blinded multicenter studies (e.g., vMap Study in *Circulation: Arrhythmia and Electrophysiology*) validated its precision against gold-standard ablations.[4][7] CE Mark approval followed, unlocking Europe after 2,000+ U.S. procedures, while December 2025 FDA clearance for next-gen features marked accelerated evolution toward scalable, hardware-free SaMD.[1][2]
Vektor rides the AI-digital health wave in cardiology, where arrhythmias drive massive unmet needs amid aging populations and rising ablation demands.[3] Timing aligns with post-COVID emphasis on efficient, non-invasive tools—vMap complements invasive systems, cutting times and risks while enabling broader access via SaMD.[1][2] Market tailwinds include AI regulatory momentum (multiple FDA/CE clearances) and integration with electroanatomic platforms, positioning it amid $10B+ EP market growth fueled by AF/VT prevalence.[1][7] It influences the ecosystem by setting a non-invasive standard, boosting ablation efficacy (e.g., arrhythmia-free survival), and paving AI partnerships in cardiac care.[2][4]
Vektor is primed for explosive scaling as SaMD unlocks hardware-free adoption across global health systems, with atrial flutter clearance and Euro entry accelerating revenue.[1][2] Trends like AI workflow automation and hybrid EP tech will amplify vMap's edge, potentially dominating non-invasive mapping amid rising arrhythmia burdens. Expect partnerships, expanded indications, and outcome data to cement its role—transforming Vektor from U.S. pioneer to global arrhythmia leader, directly advancing the vMap revolution in rapid, precise cardiac care.[1][3]
Vektor Medical has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $25.0M Series A | Solas BioVentures |